- The FDA panel has halted Pfizer's efforts to expand the use of Talzenna for a broader patient base.
- Analyst projections suggest a potential 25% upside in Pfizer's stock value.
- GuruFocus estimates reveal an 18.36% potential rise from current stock prices.
In a recent development, an FDA expert panel has decided against Pfizer's (PFE, Financial) proposal to expand the application of its prostate cancer drug, Talzenna, beyond patients with specific genetic markers. This decision is rooted in apprehensions over the lack of substantial data to support the proposed expansion, posing a potential setback to Pfizer’s strategy of broadening its treatment's market reach.
Wall Street Analysts Forecast for Pfizer Inc. (PFE, Financial)
According to projections from 21 financial analysts, Pfizer Inc (PFE, Financial) has an average target price of $28.81. The range of estimates varies, with a high target of $41.43 and a low of $23.00. This average target suggests a promising upside potential of 25.03% from the current trading price of $23.04. For those interested in more comprehensive details, visit the Pfizer Inc (PFE) Forecast page.
Brokerage Recommendations
Pfizer Inc's (PFE, Financial) market position is currently under the "Hold" category, based on the consensus recommendations from 25 brokerage firms. The overall rating is 2.6 on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 indicates Sell. This neutral rating reflects the cautious optimism associated with Pfizer's future performance.
GuruFocus Valuation Insights
From the lens of GuruFocus estimates, Pfizer Inc (PFE, Financial) is expected to reach a GF Value of $27.27 within a year, which denotes an upside potential of 18.36% from its current price of $23.04. The GF Value is a proprietary estimate that reflects the fair value a stock should trade at, derived from historical trading multiples, past business growth, and anticipated future performance. More details and data are accessible on the Pfizer Inc (PFE) Summary page.
